Pioneering AMP Innovation for Next-Generation Therapeutics
Our lead candidate, P113, derived from human salivary protein histatin-5, shows broad-spectrum antifungal and antibacterial activity with a novel mechanism:
binds cell walls → penetrates cells → disrupts metabolism,
reducing resistance risk and enabling next-generation antifungal therapy.
Understanding Candidiasis
Candidiasis is an infection caused by Candida yeasts. Candida normally lives on the skin, mouth/throat, gut, and vagina without causing problems. Infections arise when the balance of microbes is disturbed (for example, after antibiotics) or the immune system is weakened; presentations include oral thrush and vaginal yeast infections, and in high-risk settings can become invasive.
P113 AMP: A Novel Solution
P113 has shown clinically meaningful activity for oral candidiasis (mouthrinse formulations, also known as PAC-113). In Phase I/II trials in HIV-positive patients with thrush, cure or clinical response rates were comparable to nystatin and the product was generally safe and well tolerated.  
Laboratory and translational studies also support P113’s antifungal breadth and mechanistic advantages (rapid killing, intracellular targeting) against Candida spp., with next-generation P113 variants improving stability and anti-biofilm activity.
Key Attributes of P113
Clinical Development Pipeline
P113
| Generic Name | Phase 1 2 3 F | ||
| P113 |
Swipe left to view all
Precision Diagnostic Solutions
At General Biologicals Corporation (GBC), we design, develop, and manufacture diagnostic tests, instruments, and digital solutions that transform the way clinicians and laboratories deliver care.
For over 40 years, GBC has been at the forefront of in-vitro diagnostics (IVD) innovation, combining scientific expertise with cutting-edge technology to improve health outcomes worldwide.
Innovating In-Vitro Diagnostics
Since our founding in 1984, GBC has led the development of hepatitis and retrovirus diagnostic solutions and expanded into oncology, infectious diseases, fertility, blood-borne viruses, and emerging pathogens.
By leveraging ELISA, CLIA, and real-time PCR platforms, we deliver precision diagnostic tools trusted by hospitals, clinical laboratories, and pharmaceutical companies in 40+ countries.
In-vitro diagnostics are critical tools for early detection, disease management, and preventive care. GBC’s solutions empower healthcare professionals to diagnose accurately, treat effectively, and improve patient outcomes.
Automated Diagnostic Systems
To enhance laboratory efficiency and accuracy, GBC has developed automated diagnostic instruments that integrate seamlessly with our IVD reagents and testing platforms.
Key Benefits of GBC Systems:
- Rapid turnaround times for high-volume testing
- Reliable and reproducible results
- Reduced manual workload for technicians
- Scalability for growing diagnostic needs
Our innovations, including the GBC AIO M160 multi-functional analyzer and CellBio™ CTC platform, streamline diagnostic workflows and enable laboratories to deliver better patient care faster.
Our Products
Diagnostic Solutions
Diagnostic Solutions
COVID-19 Solution
Laboratory Tests (Detecting SARS-CoV-2 in currently infected patients)
GB SARS-CoV-2 Influenza A/B Multiplex PCR (Flu A/B, N)
GB SARS-CoV-2 Real-Time RT-PCR Multiplex Kit (E / N / ORF1ab)
Laboratory Tests (Detecting a patient’s immune response to SARS-CoV-2)
Point-of-Care